ALS drug will be pulled from US market after study showed patients didn't benefit

  • 📰 KPRC2
  • ⏱ Reading Time:
  • 32 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 68%

Health Berita

Washington News,Business

The maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market.

ASK 2: What should you do when a driver comes to an intersection with a flashing yellow left turn arrow?Business

Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company executives said in a statement.

Relyvrio is a powder that combines two older drugs: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 80. in İD

Indonesia Berita Terbaru, Indonesia Berita utama